ARKG
ARK Genomic Revolution ETF
Price Chart
Latest Quote
$32.93
+0.08 (+0.24%)
Current Price
| Previous Close | $32.85 |
| Open | $33.06 |
| Day High | $33.18 |
| Day Low | $32.48 |
| Volume | 1,265,229 |
Fund Information
| Net Assets | $1.31B |
| Expense Ratio | 0.75% |
| Category | Health |
| Fund Family | ARK ETF Trust |
| Net Asset Value | $33.48 |
| Premium/Discount | -1.65% |
| Exchange | BTS |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $32.31 |
| SMA50 | $30.57 |
| SMA200 | $29.45 |
| RSI | 61.22 |
| ATR | 1.7021 |
| Rel Volume | 1.15 |
Performance History
| Week | +0.18% |
| Month | +12.96% |
| Quarter | +26.97% |
| 6 Months | +7.38% |
| YTD | +14.70% |
| Year | +37.91% |
| 3 Years | -1.27% |
| 5 Years | -59.49% |
| 10 Years | +111.01% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $33.47 | 3,479,400 |
| 2026-06-11 | $33.65 | 3,199,500 |
| 2026-06-10 | $32.85 | 1,916,600 |
| 2026-06-09 | $33.56 | 3,505,400 |
| 2026-06-08 | $33.15 | 1,986,200 |
| 2026-06-05 | $33.41 | 4,377,600 |
| 2026-06-04 | $36.27 | 6,959,500 |
| 2026-06-03 | $33.92 | 4,256,000 |
| 2026-06-02 | $34.00 | 2,376,100 |
| 2026-06-01 | $34.75 | 3,630,800 |
| 2026-05-29 | $34.64 | 3,726,400 |
| 2026-05-28 | $34.12 | 3,368,100 |
| 2026-05-27 | $32.06 | 2,342,400 |
| 2026-05-26 | $31.30 | 1,504,300 |
| 2026-05-22 | $30.67 | 2,056,300 |
| 2026-05-21 | $30.53 | 1,969,100 |
| 2026-05-20 | $29.54 | 2,305,400 |
| 2026-05-19 | $28.12 | 2,796,700 |
| 2026-05-18 | $28.11 | 1,915,200 |
| 2026-05-15 | $28.15 | 2,695,400 |
| 2026-05-14 | $29.18 | 1,338,000 |
| 2026-05-13 | $29.63 | 1,090,100 |
About ARK Genomic Revolution ETF
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.